EVOLUTION AT MERCK - INVENTING FOR LIFE

BROAD ONCOLOGY STRATEGY TO IMPROVE OUTCOMES FOR CANCER PATIENTS GLOBALLY * Broadly explore combinations to reach more patients KEYTRUDA (pembrolizumab) Injection 100 mg ¹Peloton acquisition expected to close in 3Q 2019 LENVIMA (lenvatinib) capsules 10 mg and 4 mo Peloton Lynparza olaparib Viralytics Tilos THERAPEUTICS Developers of Oncolytic Immunotherapies Therapeutics MERCK INVENTING FOR LIFE Advance pipeline and pursue strategic collaborations and acquisitions to expand portfolio Identify patients most likely to benefit using biomarkers Establish KEYTRUDA as foundational treatment across most tumor types and stages of disease # Dr. Roy Baynes H | 48

View entire presentation